Here are five points:
1. The shares bought are valued at approximately $2.06 million.
2. The company currently has an average rating of “buy” and an average target price of $58.54 from all brokerages covering the firm.
3. NuVasive stock has a 50-day moving average price of $46.90 and a 200-day moving average price of $48.38.
4. NuVasive has a 52-week low of $36.81 and a 52-week high of $56.61.
5. The company’s stock has a market capitalization of $2.53 billion.
More articles on devices:
47 spine, orthopedic devices receive FDA 510(k) clearance in March
Kenai Spine debuts exoskeleton bionic robot — 5 highlights
Amedica shares gain 23.93% following Weigao Orthopedic partnership agreement: 3 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
